Here is a macroeconomic analysis for Amgen Inc. for the second quarter of 2024:

Q2 2024 Macroeconomic Analysis for Amgen Inc.
Date: August 6, 2024

Revenue:
- Amgen's total revenues increased 20% year-over-year to $8.4 billion in Q2 2024, driven by a 20% increase in product sales to $8.0 billion.
- U.S. product sales grew 23% while rest of world (ROW) sales grew 13%, indicating continued strong demand globally.

Revenue Drivers:
- The growth was primarily driven by volume increases of 26%, partially offset by a 3% decline in net selling prices.
- Newly acquired products from Horizon Therapeutics (TEPEZZA, KRYSTEXXA) contributed $1.1 billion.
- Other key drivers were Repatha, TEZSPIRE, Prolia and EVENITY, which saw strong volume growth.

Profitability:
- Gross margin declined to 61.4% from 72.9% a year ago, due to higher amortization of Horizon acquisition intangibles and royalties.
- Operating margin was 22.7% versus 38.4% in Q2 2023, impacted by higher cost of sales and operating expenses from the Horizon acquisition.
- EPS decreased 46% to $1.38, reflecting the impact of acquisition costs.

Cash Flow:
- Operating cash flow in the first half was $3.1 billion, down from $5.2 billion a year ago, due to timing of tax payments.
- Capital expenditures were $468 million in the first half for manufacturing expansion projects.

Debt and Shareholder Returns:  
- Long-term debt was $57.1 billion at quarter-end, down from $63.2 billion at year-end 2023.
- Paid $2.4 billion in dividends and repaid $1.8 billion of debt in the first half of 2024.
- No share repurchases in Q2 2024. $7.0 billion remaining under the repurchase authorization.

Guidance:
- Management expects continued product sales growth in 2024 from Horizon products and other key brands, partly offset by price declines.
- Highlighted risks from uncertain macroeconomic conditions, healthcare cost pressures and new drug pricing legislation.

Key Highlights:
- Revenue growth driven by acquisitions and strong volume demand for key innovative medicines.
- Profitability impacted by acquisition costs but cash flows remain robust to support investments and shareholder returns.
- Facing industry-wide pricing pressures and uncertainties from new drug pricing laws like the Inflation Reduction Act.
- Continuing to invest in manufacturing capacity and R&D pipeline for long-term growth.

I've provided a detailed analysis covering Amgen's quarterly performance across revenues, profitability, cash flows, capital allocation, and the management's perspective on the results and outlook. Please let me know if you need any clarification or have additional questions.